Intelligent Bio Solutions Receives Non-Dilutive Grant Funding of USD $1.43 Million
Grant Funding received to date from the Australian Federal Government totals USD $3.25 million NEW…
Grant Funding received to date from the Australian Federal Government totals USD $3.25 million NEW…
Grant Funding received to date from the Australian Federal Government totals USD $3.25 million NEW…
FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
Sequantrix identifies and validates novel, antifibrotic targets by leveraging one of the world’s largest human…
Sequantrix identifies and validates novel, antifibrotic targets by leveraging one of the world’s largest human…
Has served in interim role since January 2023 HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE)…
Has served in interim role since January 2023 HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE)…
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patients MUNICH,…
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patients MUNICH,…
– Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient…
– Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient…
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals…
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals…
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corp. (NASDAQ: PDSB), a…
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corp. (NASDAQ: PDSB), a…
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation…
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation…
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary…
Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary…